インドのバイオジェネリック薬市場

Abstract

Escalation of drug development costs, and low success rates have forced bio-pharmaceutical companies to focus on developing countries to set up a base. Growing aged population, escalating healthcare costs have forced Healthcare authorities around the world to favour cost-effective generic drugs over unaffordable Branded Biopharmaceuticals. This has opened vistas of opportunities for well established players like India, which is already established in the Chemical Generics market.

This Research Service explores key trends, Drivers, Restraints as well as Challenges faced by the evolving Indian Biogenerics industry through a study of prominent Biogeneric drugs manufactured in India and outlines strategies, based on the same.

Table of Contents

• 1. THE INDIAN BIOGENERICS MARKET
  • Executive Summary
    • 1. Introduction
    • 2. Introduction
    • 3. Overview of the Global Biogenerics Market
    • 4. Overview of the Indian Biogenerics Market
  • Market Analysis and Trends
    • 1. Industry Challenges
    • 2. Market Drivers
    • 3. Market Restraints
    • 4. Opportunities for the Indian Biogenerics Market
  • Product Analysis of the Indian Biogenerics Market
    • 1. Recombinant Human Erythropoietin (rhu EPO)
    • 2. Recombinant Human Interferon Alpha (rhu IFN-alpha)
    • 3. Recombinant Human Granulocyte Colony Stimulating Factor (rhu G-CSF)
    • 4. Recombinant Human Insulin
    • 5. Other Biogenerics
  • Strategic Conclusions and Recommendations
    • 1. Strategic Conclusions
    • 2. Strategic Recommendations